Immuneering (IMRX) CLO awarded 176,000 stock options at $4.91 exercise price

Rhea-AI Filing Summary

Immuneering Corp’s chief legal officer and secretary, Michael Bookman, received a new stock option grant. On February 3, 2026, he was awarded options to purchase 176,000 shares of Class A common stock at an exercise price of $4.91 per share.

The options vest in equal monthly installments over four years starting February 1, 2026, and will be fully vested and exercisable on January 1, 2030. All 176,000 derivative securities are reported as directly owned following this grant.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bookman Michael

(Last) (First) (Middle)

245 MAIN STREET

SECOND FLOOR

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immuneering Corp [ IMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF LEGAL OFFICER, SECRETARY

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$4.91	02/03/2026		A		176,000		(1)	02/03/2036	Class A Common Stock	176,000	$0	176,000	D

Explanation of Responses:

1. The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030.

Remarks:

	/s/ Michael D. Bookman	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Immuneering (IMRX) disclose about Michael Bookman’s compensation?

Immuneering disclosed that chief legal officer and secretary Michael Bookman received a stock option grant for 176,000 shares. The options have a $4.91 exercise price and vest monthly over four years, aligning his potential upside with long-term shareholder value.

How many stock options did Immuneering’s Michael Bookman receive in this Form 4?

Michael Bookman received stock options covering 176,000 shares of Immuneering Class A common stock. This derivative award was granted on February 3, 2026 and is reported as directly owned following the transaction, reflecting a sizable equity-based component in his compensation package.

What is the exercise price of the Immuneering (IMRX) options granted to Michael Bookman?

The stock options granted to Michael Bookman carry an exercise price of $4.91 per share. This means he can buy Immuneering Class A common stock at $4.91 once options vest and are exercised, potentially benefiting if the market price exceeds that level.

How do the newly granted Immuneering options vest for Michael Bookman?

The options vest in equal monthly installments over a four-year period beginning February 1, 2026. According to the filing, they will be fully vested and exercisable on January 1, 2030, creating a long-term incentive structure for Immuneering’s chief legal officer.

Are Michael Bookman’s newly granted Immuneering options held directly or indirectly?

The Form 4 shows that all 176,000 stock options are held directly by Michael Bookman. There is no indication of indirect ownership through entities or family members, and the ownership form in the derivative securities table is marked as direct (D).

What role does Michael Bookman hold at Immuneering (IMRX) in this Form 4?

Michael Bookman is identified as an officer of Immuneering, serving as chief legal officer and secretary. The Form 4 does not list him as a director or 10% owner, but highlights his executive role tied to the reported stock option grant.